Discussion questions, not orders

Rationale. Formation markers are not documented in the public ledger; CTX alone (upper-normal, fasting unknown) cannot establish formation–resorption uncoupling. BTM use for monitoring/interpretation and sex-specific reference intervals are the relevant literature (not densitometry-only guidance).

Rationale. ISCD 2023 Adult Official Positions (lit-0015 / Shuhart et al. J Clin Densitom 2023 doi 10.1016/j.jocd.2023.101435): Z-scores preferred in men <50; osteoporosis cannot be diagnosed on BMD alone under 50; each facility should determine precision error and calculate LSC (manufacturer LSC not a substitute) for serial change; TBS is appropriate in adults ≥40 (male fracture-risk evidence primarily studied above age 50) and routine TBS-change monitoring is not recommended; VFA has formal indication criteria not met by young age + low BMD alone without other triggers. Age ~38 at latest scans — all four points are carried on the lit-0015 card quality_notes/body.

Rationale. Serial 24h urine calcium values 283→254→333 mg/24h in a male (common male threshold often 300 mg/day or 4 mg/kg; 2 of 3 collections below 300; middle value 254 normal at performing lab ref 100–300 vs Litholink 40–250). Mechanism (absorptive vs renal leak vs resorptive) incomplete; high urine Na noted. Counter-consideration from AUA 2014 Statement 7 (Recommendation, Grade C) — clinicians should NOT routinely perform "fast and calcium load" testing to distinguish among types of hypercalciuria, because it has not been shown to change clinical practice — and that guideline population is stone formers, whereas this record documents one lifetime stone, passed spontaneously, and no stones on the CT urogram of 2026-02-27. That is a stone-forming history at its mildest end rather than an absence of one, so the guideline population overlaps this record weakly rather than not at all (COR-0042). Sodium-aware 24-h panel framing (AUA Statement 6) is the better-supported element; mechanism-classification testing remains a research question, not a mandated order.

Rationale. Best single-primary research alternative remains genetically untested; yield honesty required (not high-yield marketing).

Rationale. Prior KIT-negative report lacks method/LOD; consensus mast-cell diagnostic pathways require sensitive KIT D816V methods. Negative results without documented assay quality do not fully exclude low-burden disease. (HαT explains basal tryptase separately and is not a substitute citation for KIT methodology.)

Rationale. Baseline titers are not a vaccine-challenge study; formal SAD criteria require response assessment and infection history.

Rationale. Copper not documented in public pack; copper-deficiency myeloneuropathy can present with neurologic findings and may lack frank cytopenias. Zinc excess is a risk context. Wilson disease (copper overload) is a different problem and is not the citation basis here.

Rationale. Modern SFN criteria require objective testing; symptoms alone are insufficient.

Rationale. IDSA babesiosis: smear or PCR for confirmation. Specialty FISH/IgM remain contested LDTs; commercial PCR/IB negative on pack.

Rationale. Historical T≈34 is reported_history with incomplete instrument provenance; Endocrine Society hypogonadism guidance informs HPG-axis reconstruction. Karyotype/CMA is a separate cytogenetic indication question (e.g., Klinefelter workup pathways), not established by testosterone-therapy guidelines alone.